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In the absence of experimental 3D structures at atomic resolution for the entire
CFTR protein, homology models were built from 3D experimental structures of
ABC exporters. These models provide valuable insights into the structural and
functional characteristics of CFTR. These initial models were recently enriched
by other modeling studies and molecular dynamics, offering a description of the
possible architecture of the anion channel as a “bottleneck” with a signiﬁcant
narrowing of the pore.
We performed molecular dynamics experiments from our model of the open form
of CFTR protein made by homology on the Sav1866 template. This model was
validated using structural information provided by new experimental 3D structures
of ABC exporters, and by taking into account the internal symmetry involving
the two halves of the protein. We were able to explore the stability and the
conformational variability of the 3D structure. We obtained a relevant model of
the full open form of the anion channel, particularly well consistent with the
experimental data available today. A lateral access path for ions and molecules
from the cytosol was also highlighted.
These models provide insight into the molecular mechanisms ensuring the proper
functioning of the CFTR protein, as well as the impact of mutations in patients
with cystic ﬁbrosis (CFTR2 database). In addition, we also use models of mutated
forms of CFTR (F508del-CFTR in particular) to perform rational drug design. A
series of molecules with a potential corrective effect are currently synthesized and
their biological activity evaluated by functional tests.
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The CFTR variant c.3700A>G, predicted to cause the missense mutation p.Ile1234Val
or alternative splicing, exhibits variable CF disease severity [1]. This variant, while
rare in North America and Europe, is relatively common in the Middle East (~12%
of CF population). The purpose of this study was to determine the consequences of
this mutation. Clinical assays revealed that individuals homozygous for c.3700A>G
exhibited defective CFTR function. Genomic DNA from these patients was sequenced,
and total RNA extracted from epithelial cells was transcribed into cDNA and sequenced.
We found that this mutation in exon 19 activates a cryptic donor splice-site 18 bp
upstream of the original donor splice-site, resulting in the in-frame deletion of 6
amino acids (r.3700_3717del; p.Ile1234_Arg1239del). A CFTR cDNA clone was con-
structed containing the deletion (p.Ile1234_Arg1239del) and heterologously expressed
to test CFTR protein biosynthesis. This deletion, like the major CF-causing mutation
p.Phe508del, caused a primary defect in processing. Importantly, Lumacaftor (VX-
809), currently in clinical trial for CF patients with p.Phe508del, partially ameliorated
the processing defect exhibited by p.Ile1234_Arg1239del. These studies highlight the
need to deﬁne molecular and clinical consequences of rare CFTR variants in order to
deﬁne possible therapeutic strategies.
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Objectives: Sensitive outcome measures of CFTR function may facilitate the imple-
mentation of mutation-speciﬁc therapy with CFTR modulators in patients with cystic
ﬁbrosis with non-G551D mutations. Intestinal current measurement (ICM) is a sensitive
assay for functional assessment of mutant CFTR in rectal biopsies and was recently
shown to detect potentiator effects of 1-EBIO ex vivo (Roth E. et al., PLOS One 2011).
The aim of this study was to determine, if ICM is sensitive to detect potentiation
of CFTR-mediated Cl− secretion in rectal epithelia from CF patients with a G551D
mutation treated with ivacaftor.
Methods: Rectal biopsies were obtained from 8 patients carrying a G551D-CFTR
mutation before and at least four weeks after the start of ivacaftor therapy. Rectal
tissues were mounted in micro-Ussing chambers and CFTR-mediated Cl− secretion
was determined from Cl− secretory responses induced by cAMP (IBMX/forskolin)-
and Ca2+ (charbachol)-mediated stimulation.
Results: Before ivacaftor therapy, ICM detected variable residual CFTR-mediated Cl−
secretion in rectal tissues from CF patients with a G551D mutation. In the presence
of ivacaftor therapy, CFTR-mediated Cl− secretory responses were increased in all 8
patients.
Conclusion:We conclude that ICM is sensitive to detect in vivo potentiation of mutant
CFTR function by treatment with ivacaftor. Our results indicate that ICM may be a
useful bioassay to determine therapeutic responses at the level of the basic CF defect
of ivacaftor and potentially other clinical CFTR modulators in CF patients with non-
G551D mutations.
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We report the case of young baby boy born in Romania, admitted to our emergency
department at the age of 1 month for severe neonatal cholestasis associated with
coagulation dysfunction and pulmonary infection with multiple pathogens. The
ﬁrst hypothesis was a immune deﬁciency but not conﬁrmed. The Guthrie test
performed at that time was normal for the CF screening, but evidenced a MCAD,
which was subsequently conﬁrmed by the presence of the mutation C985A>G. The
appropriate food regimen was started. Because of continued clinical deterioration
and of lack of diagnosis despite broad etiological research, a sweat test was
performed at 2 months of age, pathological. The screening of the CFTR gene
conﬁrmed CF diagnosis and found a rare homozygous mutation c.1853_1863del.
Fecal elastase was low. Despite aggressive medical and surgical management, he
developed severe portal hypertension and ascitis. A liver transplant is considered.
Nevertheless, he developed a recurrent right chylothorax, trachebronchomalacia
with life-threatening obstructions, and pulmonary infection with Pseudomonas
aeruginosa and Staphylococcus aureus. Unfortunately, this child died at the age
of 7 months.
Conclusion: This case is of interest for several reasons: (a) This genotype was
never described before, (b) and is associated here with very early and severe hepatic
dysfunction, which is unusual in CF, (3) the association of CF and MCAD was never
reported.
